Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 52-year-old man comes to the clinic due to a new-onset tremor and headaches over the past 3 days. He underwent a deceased-donor renal transplantation 8 months ago for end-stage renal disease secondary to hypertensive nephrosclerosis. His maintenance immunosuppression regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Two weeks ago, he was diagnosed with esophageal candidiasis by his primary care physician and was started on a 14-day course of oral fluconazole. His temperature is 37.1°C (98.8°F), blood pressure is 168/95 mmHg (baseline 125/80 mmHg), and heart rate is 82/min. Physical examination reveals a fine resting tremor in both hands. The renal allograft is non-tender to palpation.

Laboratory studies show:
Blood urea nitrogen: 42 mg/dL
Serum creatinine: 2.7 mg/dL (baseline 1.3 mg/dL)
Serum potassium: 5.2 mEq/L
Urinalysis: Trace protein, no red blood cells, no white blood cells

Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Administer intravenous pulse methylprednisolone
  2. B
    Add amlodipine and continue the current medication regimen
  3. Measure serum tacrolimus trough level and withhold the next doseAnswer
  4. D
    Recommend ibuprofen for headaches and reevaluate in one week
  5. E
    Perform an ultrasound-guided percutaneous allograft biopsy

Answer

The most appropriate next step is to measure the serum tacrolimus trough level and withhold the next dose.
The correct answer is to measure the serum tacrolimus trough level and withhold the next dose. This patient's clinical presentation—acute kidney injury (AKI), new-onset hypertension, and neurologic symptoms (tremor, headaches)—is highly characteristic of calcineurin inhibitor (CNI) toxicity. Tacrolimus is heavily metabolized in the liver and intestines by the cytochrome P450 3A4 (CYP3A4) enzyme system. Fluconazole is a well-known, potent inhibitor of CYP3A4. When fluconazole was initiated for esophageal candidiasis, it significantly decreased the clearance of tacrolimus, leading to supratherapeutic serum levels. Elevated tacrolimus levels cause potent afferent arteriolar vasoconstriction, leading to acute nephrotoxicity and hypertension. Neurotoxicity is another classic dose-dependent side effect. The most appropriate next step in monitoring and management is to measure the serum tacrolimus trough level to confirm toxicity and immediately withhold the medication. Once the level falls back into the therapeutic range, tacrolimus can be restarted at a lower, carefully monitored dose while the patient completes the fluconazole course.

Step-by-Step Solution

1
Analyze the patient's presentation and longitudinal data.
The patient developed acute kidney injury, new-onset hypertension, and neurotoxicity (tremor, headaches) shortly after starting fluconazole.
Identifying temporal relationships between new medications and symptom onset is critical in transplant patients.
2
Identify the pharmacological interaction.
Fluconazole strongly inhibits the CYP3A4 enzyme, which is responsible for the metabolism of tacrolimus.
Decreased metabolism leads to the toxic accumulation of tacrolimus in the serum.
3
Determine the appropriate management protocol.
The immediate priority is to confirm the suspected toxicity via drug levels and stop further accumulation by withholding the drug.
Checking the trough level confirms the diagnosis, and withholding the dose prevents worsening of the acute kidney injury and neurotoxicity.

Key Concept

Calcineurin inhibitor toxicity (e.g., tacrolimus) often presents with acute kidney injury, hypertension, and neurotoxicity, and can be precipitated by CYP3A4 inhibitors like azole antifungals. The initial management is to check trough levels and withhold the offending drug.
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic